Novel Biomarker Predicts Dementia Risk
|
By LabMedica International staff writers Posted on 18 Dec 2019 |
|
Image: Crystal structure of CD14 protein and its implications for lipopolysaccharide signaling (Photo courtesy of Wikimedia Commons)
A new biomarker related to brain atrophy, cognitive decline, and dementia was described in a recently published paper.
Investigators at the University of Texas Health Science Center at San Antonio (USA) compared risk of dementia to levels of the biomarker sCD14 in 1,588 participants from the Framingham Heart Study and 3,129 participants from the Cardiovascular Health Study.
The protein encoded by the CD14 gene is a surface antigen that is preferentially expressed on monocytes and macrophages. It cooperates with other proteins to mediate the innate immune response to bacterial lipopolysaccharide. CD14 exists in two forms, one anchored to the membrane by a glycosylphosphatidylinositol tail (mCD14), the other a soluble form (sCD14). Soluble CD14 either appears after shedding of mCD14 or is directly secreted from intracellular vesicles.
Investigators measured levels of plasma sCD14 in samples of participants’ blood at the time they enrolled in the study. In the Framingham group, brain MRI and cognitive testing were performed within one year after measurement of sCD14. A second round of tests was performed after seven years. Surveillance for dementia was conducted over an average of nine years. In the Cardiovascular Health Study group, the first brain MRI was obtained three to four years after enrollment and a second round five years later.
Mean age of the members of the Framingham group was 69 ± 6 years, 47% male (131 incident events), and the mean age of the Cardiovascular Health Study group was 72 ± 5 years, 41% male (724 incident events). Meta-analysis across the two cohorts showed that each SD unit increase in sCD14 was associated with a 12% increase in the risk of incident dementia following adjustments for age, sex, APOE epsilon4 status, and vascular risk factors.
"We have strong reason to believe that sCD14 can be a useful biomarker to assess a person's risk of cognitive decline and dementia," said contributing author Dr. Sudha Seshadri, professor of neurology at the University of Texas Health Science Center at San Antonio. "The most exciting part is that we could assess this risk in advance, when there is ample time to intervene and change the course of a person's life."
The study was published in the December 9, 2019, online edition of the journal Neurology.
Related Links:
University of Texas Health Science Center at San Antonio
Investigators at the University of Texas Health Science Center at San Antonio (USA) compared risk of dementia to levels of the biomarker sCD14 in 1,588 participants from the Framingham Heart Study and 3,129 participants from the Cardiovascular Health Study.
The protein encoded by the CD14 gene is a surface antigen that is preferentially expressed on monocytes and macrophages. It cooperates with other proteins to mediate the innate immune response to bacterial lipopolysaccharide. CD14 exists in two forms, one anchored to the membrane by a glycosylphosphatidylinositol tail (mCD14), the other a soluble form (sCD14). Soluble CD14 either appears after shedding of mCD14 or is directly secreted from intracellular vesicles.
Investigators measured levels of plasma sCD14 in samples of participants’ blood at the time they enrolled in the study. In the Framingham group, brain MRI and cognitive testing were performed within one year after measurement of sCD14. A second round of tests was performed after seven years. Surveillance for dementia was conducted over an average of nine years. In the Cardiovascular Health Study group, the first brain MRI was obtained three to four years after enrollment and a second round five years later.
Mean age of the members of the Framingham group was 69 ± 6 years, 47% male (131 incident events), and the mean age of the Cardiovascular Health Study group was 72 ± 5 years, 41% male (724 incident events). Meta-analysis across the two cohorts showed that each SD unit increase in sCD14 was associated with a 12% increase in the risk of incident dementia following adjustments for age, sex, APOE epsilon4 status, and vascular risk factors.
"We have strong reason to believe that sCD14 can be a useful biomarker to assess a person's risk of cognitive decline and dementia," said contributing author Dr. Sudha Seshadri, professor of neurology at the University of Texas Health Science Center at San Antonio. "The most exciting part is that we could assess this risk in advance, when there is ample time to intervene and change the course of a person's life."
The study was published in the December 9, 2019, online edition of the journal Neurology.
Related Links:
University of Texas Health Science Center at San Antonio
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG
Latest Molecular Diagnostics News
- Novel Method Combining Nano Informatics and AI Paves Way for Cancer Blood Tests
- Groundbreaking Molecular Diagnostic Kit to Provide Lyme Disease Detection in Minutes
- New Assay Detects Heart Failure Biomarker in Less than 11 Minutes
- Innovative Test Improves Assessment of Patients with Mild Traumatic Brain Injury
- New Method for Lung Microbiomes Analysis Predicts Mortality in Children after Bone Marrow Transplant
- Novel Technique Detects Biomarkers for Kidney Diseases with Nephritic Syndrome
- Lipoprotein Blood Test Detects Hereditary Cardiovascular Risk
- Whole Genome Sequencing Detects Infection Transmission in NICU
- Novel Inexpensive, Shelf-Stable, Easy To Use Tests Bring Lab-Level Precision at POC
- World’s First One-Minute Hepatitis C Antibody Test Facilitates Quick Triage
- Game-Changing Blood Test for Stroke Detection Could Bring Life-Saving Care to Patients
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
Channels
Clinical Chemistry
view channel
New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections
Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more
3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more.jpg "Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)")
POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more
Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
The conventional methods for measuring free cortisol, the body's stress hormone, from blood or saliva are quite demanding and require sample processing. The most common method, therefore, involves collecting... Read moreHematology
view channel
Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more
First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
Arboviruses represent an emerging global health threat, exacerbated by climate change and increased international travel that is facilitating their spread across new regions. Chikungunya, dengue, West... Read more
POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read moreImmunology
view channel
Blood Test Measures Immune Response to Epstein-Barr Virus in MS Patients
Multiple sclerosis (MS) is a chronic neurological condition for which there is currently no cure. It affects around three million people globally and ranks as the second most common cause of disability... Read more.jpg "Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)")
AI Predicts Tumor-Killing Cells with High Accuracy
Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more
Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more
AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
Current strategies for matching cancer patients with specific treatments often depend on bulk sequencing of tumor DNA and RNA, which provides an average profile from all cells within a tumor sample.... Read moreMicrobiology
view channel
Integrated Solution Ushers New Era of Automated Tuberculosis Testing
Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
Sepsis affects up to 50 million people globally each year, with bacteraemia, formerly known as blood poisoning, being a major cause. In the United States alone, approximately two million individuals are... Read more
Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more
Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
Antimicrobial resistance (AMR) is a serious global public health concern that claims millions of lives every year. It primarily results from the inappropriate and excessive use of antibiotics, which reduces... Read morePathology
view channel
AI Tool Detects Tiny Protein Clumps in Microscopy Images in Real-Time
Over 55 million individuals worldwide suffer from dementia-related diseases like Alzheimer's and Parkinson's. These conditions are caused by the clumping together of the smallest building blocks in the... Read more
New Tool Enables Better Classification of Inherited Disease-Causing Variants
Whole genome and exome sequencing are increasingly available for clinical research, aiding in the detection of inherited genetic variants that may cause various diseases. The American College of Medical... Read more
Groundbreaking CRISPR Screen Technology Rapidly Determines Disease Mechanism from Tissues
Thanks to over a decade of advancements in human genetics, scientists have compiled extensive lists of genetic variations linked to a wide array of human diseases. However, understanding how a gene contributes... Read more
Technology
view channel
Microneedle Patch Detects Skin Cancer Early
Wearable bioelectronics has emerged as a significant innovation in healthcare, especially in the field of biosensing, providing a new method to monitor individual health for both diagnostic and therapeutic purposes.... Read more
New Diagnostic System Achieves PCR Testing Accuracy
While PCR tests are the gold standard of accuracy for virology testing, they come with limitations such as complexity, the need for skilled lab operators, and longer result times. They also require complex... Read more
Industry
view channel
Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing
Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
Unlike severe traumatic brain injury (TBI), mild TBI often does not show clear correlations with abnormalities detected through head computed tomography (CT) scans. Consequently, there is a pressing need... Read more
Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
Beckman Coulter Diagnostics (Brea, CA, USA) and MeMed BV (Haifa, Israel) have expanded their host immune response diagnostics partnership. Beckman Coulter is now an authorized distributor of the MeMed... Read more_1.jpg "Image: Thermo Fisher will distribute Bio-Techne products across Europe (Photo courtesy of 123RF)")